Novo received CHMP backing for its preventive hemophilia A preventive drug, adding to a broader September slate of CHMP recommendations. Alongside the hemophilia indication, the committee recommended approval for seven other new medicines and 11 label expansions. The CHMP opinion is a regulatory milestone that can accelerate EU market entry planning, particularly for chronic, lifelong therapies where treatment continuity is central. Hemophilia A preventive regimens are also an area of intense competitive positioning as new products aim to improve dosing convenience and outcomes. The briefing frames the CHMP outcome as a multi-program endorsement, suggesting sustained regulator attention across both rare disease and wider pipeline updates.